Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Immunotherapy. --- Cancer --- Genetic engineering. --- Treatment. --- T cells. --- Neoplasms --- Receptors, Antigen, T-Cell --- T-Lymphocytes --- Immunotherapy, Adoptive. --- therapy. --- therapeutic use. --- immunology. --- Adoptive Immunotherapy --- CAR T-Cell Therapy --- Cellular Immunotherapy, Adoptive --- Chimeric Antigen Receptor Therapy --- Immunotherapy, Adoptive Cellular --- Adoptive Cellular Immunotherapy --- Adoptive Cellular Immunotherapies --- Adoptive Immunotherapies --- CAR T Cell Therapy --- CAR T-Cell Therapies --- Cellular Immunotherapies, Adoptive --- Immunotherapies, Adoptive --- Immunotherapies, Adoptive Cellular --- T-Cell Therapies, CAR --- T-Cell Therapy, CAR --- Therapies, CAR T-Cell --- Therapy, CAR T-Cell --- Receptors, Chimeric Antigen --- Killer Cells, Lymphokine-Activated --- Cytapheresis --- Lymphocytes, Tumor-Infiltrating --- Monocytes, Activated Killer --- Designed genetic change --- Engineering, Genetic --- Gene splicing --- Genetic intervention --- Genetic surgery --- Genetic recombination --- Biotechnology --- Transgenic organisms --- Cancer therapy --- Cancer treatment --- Therapeutic immunology --- Clinical immunology --- Therapeutics --- T lymphocytes --- Thymus-dependent cells --- Thymus-dependent lymphocytes --- Thymus-derived cells --- Lymphocytes --- Therapy --- Immunological aspects --- Treatment

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.

Research & information: general --- Chemistry --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody–drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- n/a --- antibody-drug conjugate

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML.

Research & information: general --- Chemistry --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody-drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy --- acute lymphoblastic leukemia --- pediatric --- advances --- diagnosis --- treatment --- immunotherapy --- bispecific T-cell engager (BiTE) --- BCP-ALL --- leukemia --- TRAIL --- antibody --- Fc-engineering --- xenograft --- CD19 --- juvenile myelomonocytic leukemia --- RAS signaling --- hematopoietic stem cell transplantation --- 5-azacitidine --- myelodysplastic/myeloproliferative disorders --- targeted therapy --- ADC --- antibody-drug conjugate --- pediatric leukemia --- ALL --- AML --- allogeneic stem cell transplantation --- acute myeloid leukemia --- minimal residual disease --- conditioning regimen --- alternative donors --- B-ALL --- DUX4 --- IKZF1 --- PAX5 --- Ph-like --- ZNF384 --- NUTM1 --- T-ALL --- NOTCH1 --- BCL11B --- transcriptome --- genome --- chronic myeloid leukemia --- CML --- tyrosine kinase inhibitor --- immunizations --- COVID-19 --- childhood acute lymphoblastic leukemia --- low-risk ALL --- risk-stratified treatment --- treatment related toxicity --- L-asparaginase --- acute pancreatitis --- polymorphism --- SNV --- ABCC4 --- CFTR --- other extramedullary relapse --- lymphoblastic leukemia --- children --- prognosis --- evolution of CAR T cells --- FDA-approved CAR products --- TcR versus CAR --- limitations and complications of CAR T cell therapy --- future directions of CAR T cell therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

T cells --- Tumor antigens. --- Receptors, Chimeric Antigen --- Neoplasms --- Immunotherapy, Adoptive. --- Receptors, Antigen, T-Cell. --- Cell- and Tissue-Based Therapy. --- Receptors. --- therapeutic use. --- therapy. --- Therapy, Cell --- Therapy, Tissue --- Cell Therapy --- Tissue Therapy --- Cell and Tissue Based Therapy --- Tissue Therapy, Historical --- Receptors, T-Cell Antigen --- T-Cell Antigen Receptor --- T-Cell Receptor --- Antigen Receptors, T-Cell --- T-Cell Receptors --- Antigen Receptor, T-Cell --- Antigen Receptors, T Cell --- Receptor, T-Cell --- Receptor, T-Cell Antigen --- Receptors, T Cell Antigen --- Receptors, T-Cell --- T Cell Antigen Receptor --- T Cell Receptor --- T Cell Receptors --- T-Cell Antigen Receptors --- CD3 Complex --- Genes, T-Cell Receptor --- Complementarity Determining Regions --- Adoptive Immunotherapy --- CAR T-Cell Therapy --- Cellular Immunotherapy, Adoptive --- Chimeric Antigen Receptor Therapy --- Immunotherapy, Adoptive Cellular --- Adoptive Cellular Immunotherapy --- Adoptive Cellular Immunotherapies --- Adoptive Immunotherapies --- CAR T Cell Therapy --- CAR T-Cell Therapies --- Cellular Immunotherapies, Adoptive --- Immunotherapies, Adoptive --- Immunotherapies, Adoptive Cellular --- T-Cell Therapies, CAR --- T-Cell Therapy, CAR --- Therapies, CAR T-Cell --- Therapy, CAR T-Cell --- Killer Cells, Lymphokine-Activated --- Cytapheresis --- Lymphocytes, Tumor-Infiltrating --- Monocytes, Activated Killer --- Antigens --- Tumor markers --- T cell receptors --- T lymphocyte antigen receptors --- Cell receptors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Genetic transformation --- Gene therapy --- Cellular therapy --- Gene Transfer Techniques. --- Genetic Therapy. --- Thérapie génique --- Thérapie cellulaire --- Cellular therapy. --- Gene therapy. --- Genetic transformation. --- Gene Transfer --- Gene Therapy --- Therapy, Gene --- Gene transfer --- Transformation (Genetics) --- DNA Therapy --- Gene Therapy, Somatic --- Genetic Therapy, Gametic --- Genetic Therapy, Somatic --- Therapy, DNA --- Therapy, Somatic Gene --- Somatic Gene Therapy --- Gametic Genetic Therapies --- Gametic Genetic Therapy --- Genetic Therapies --- Genetic Therapies, Gametic --- Genetic Therapies, Somatic --- Somatic Genetic Therapies --- Somatic Genetic Therapy --- Therapies, Gametic Genetic --- Therapies, Genetic --- Therapies, Somatic Genetic --- Therapy, Gametic Genetic --- Therapy, Genetic --- Therapy, Somatic Genetic --- Cell therapy --- Cells --- Therapy, Cellular --- Therapeutic use --- Genetic engineering --- Therapeutics --- Genetic recombination --- Microbial genetics --- Nucleic acids --- Transfection --- Gene Transfer Techniques --- Genetic Services --- Genes, Transgenic, Suicide --- Organotherapy --- Therapeutics, Physiological --- Transplantation of organs, tissues, etc. --- Cell transplantation --- Gene Transfer. --- Gene Delivery Systems --- Gene Transfer Technique --- Transgenesis --- Delivery System, Gene --- Delivery Systems, Gene --- Gene Delivery System --- Technique, Gene Transfer --- Techniques, Gene Transfer --- Transfer Technique, Gene --- Transfer Techniques, Gene --- Genetic Therapy --- Transgenes --- Genetics --- Gene Therapy. --- Gene Therap. --- Gene Transfer, Horizontal --- Genetic Structures --- Genetic Phenomena --- Recombination, Interspecific --- Gene Transfer, Lateral --- Horizontal Gene Transfer --- Lateral Gene Transfer --- Recombination, Interspecies --- Gene Transfers, Lateral --- Interspecies Recombination --- Interspecific Recombination --- Lateral Gene Transfers --- Thérapie génique. --- Transformation, Genetic. --- Genetic Transformation --- Genetic Transformations --- Transformations, Genetic --- Crosses, Genetic --- Transduction, Genetic --- Immunotherapy, Adoptive --- Adoptive Immunotherapy --- CAR T-Cell Therapy --- Cellular Immunotherapy, Adoptive --- Chimeric Antigen Receptor Therapy --- Immunotherapy, Adoptive Cellular --- Adoptive Cellular Immunotherapy --- Adoptive Cellular Immunotherapies --- Adoptive Immunotherapies --- CAR T Cell Therapy --- CAR T-Cell Therapies --- Cellular Immunotherapies, Adoptive --- Immunotherapies, Adoptive --- Immunotherapies, Adoptive Cellular --- T-Cell Therapies, CAR --- T-Cell Therapy, CAR --- Therapies, CAR T-Cell --- Therapy, CAR T-Cell --- Receptors, Chimeric Antigen --- Killer Cells, Lymphokine-Activated --- Cytapheresis --- Lymphocytes, Tumor-Infiltrating --- Monocytes, Activated Killer